Brevan Howard Capital Management LP Acquires New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brevan Howard Capital Management LP acquired a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,804 shares of the specialty pharmaceutical company's stock, valued at approximately $281,000.

Several other hedge funds also recently added to or reduced their stakes in the business. New Age Alpha Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $40,000. KBC Group NV boosted its position in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after buying an additional 982 shares during the period. Nisa Investment Advisors LLC boosted its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth $230,000.

Collegium Pharmaceutical Stock Up 0.9%

Shares of Collegium Pharmaceutical stock traded up $0.27 during trading hours on Thursday, hitting $29.34. The company had a trading volume of 364,807 shares, compared to its average volume of 401,573. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a market cap of $942.75 million, a P/E ratio of 12.65 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company's 50-day moving average is $28.13 and its two-hundred day moving average is $29.96.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.45 earnings per share. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COLL shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Piper Sandler reissued a "neutral" rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 10,445 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares of the company's stock, valued at $3,081,904.50. This trade represents a 19.42% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.